Jeremy L. Davis, M.D.

Jeremy L. Davis, M.D.
Assistant Research Physician
Director, Surgical Oncology Research Fellowship
Chief, General Surgery Consultative Services
Surgeon-in-Chief, NIH Clinical Center

Team Member of:

Dr. Jeremy L. Davis is a surgical oncologist whose research focus is in upper gastrointestinal tract malignancy, including stomach, pancreas and hepatobiliary cancers. He is the principal investigator for trials aimed at elucidating the drivers of metastasis in stomach cancers, including inherited forms of stomach cancer.  Dr. Davis also directs the Surgical Oncology Research Fellowship.

Areas of Expertise

1) gastric cancer, 2) pancreatic cancer, 3) hepatic metastasectomy, 4) minimally-invasive and robotic surgery

Contact Info

Jeremy L. Davis, M.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 4-3760
Bethesda, MD 20892
Ph: 240-858-3610
Fax: 301-451-6933

Mutation of the tumor suppressor gene CDH1 is a frequent cause of the hereditary diffuse gastric cancer (HDGC) syndrome, which is associated with gastric adenocarcinoma, lobular breast cancer, and cleft lip/palate. Loss of CDH1 gene expression in the stomach, and resultant signet ring cell formation, is considered the initial step in stomach cancer formation in patients with HDGC. Although this is a critical step in HDGC development it must be followed by other crucial changes in gastric epithelial cells, which here-to-for have not been identified.

Furthermore, gastric adenocarcinoma with diffuse-type histology and signet ring cells is increasing in incidence and disproportionately affects young and female patients. Early peritoneal (i.e. abdominal cavity) cancer spread is a unique and enigmatic feature of this cancer type. Identification of the initial genetic changes in the cells which line the stomach and lead to invasive gastric cancer may reveal markers useful for early detection and targeted therapy in both hereditary and non-hereditary forms of gastric cancer.

Our hypothesis is loss of CDH1 gene expression alone is insufficient for development of HDGC, and that additional gain or loss of other critical cancer-related genes is required for signet ring cell growth and gastric cancer progression. Disruption of the elements needed for cells to connect to (cell adhesion), communicate with (cell-cell signaling), and move about (motility) each other have all been linked to the development of gastric cancer. Our research goal is to identify the changes in stomach cells that lead to gastric cancer so that we may: (1) better select patients with CDH1 mutation for risk-reducing total gastrectomy; (2) identify targets for treatment of patients diffuse-type gastric cancer. These research discoveries may also help identify preventative treatments to reduce the risk of cancer development in patients with HDGC and therefore eliminate the need for total gastrectomy.

The gastric cancer research program is working toward these goals by: (1) Isolating and fully characterizing signet ring cancer cells from the mucosa of patients with germline CDH1 mutations; (2) Establishing critical elements for implantation and growth of gastric cancer metastases. This contribution is significant since it will establish the critical pathway(s) necessary for early diffuse gastric cancer growth and progression. Our gastric cancer research is made possible by four NCI/CCR and IRB-approved clinical studies of patients with hereditary and non-hereditary forms of gastric cancer.















NIH Scientific Focus Areas:
Cancer Biology, Clinical Research

Selected Key Publications

  1. Davis JL, Selby LV, Chou JF, Schattner M, Ilson DH, Capanu M, Brennan MF, Coit DG, Strong VE
    Ann Surg Oncol. epub: 2016. [ Journal Article ]
  2. McDuffie LA, Sabesan A, Allgäeuer M, Xin L, Koh C, Heller T, Davis JL, Raffeld M, Miettienen M, Quezado M, Rudloff U.
    J Clin Pathol. 69(9): 826-833, 2016. [ Journal Article ]
  3. Feingold PL, Kwong ML, Davis JL, Rudloff U
    J Surg Oncol. 115(2): 192-201, 2017. [ Journal Article ]
  4. Davis JL, Ripley RT
    Surg Clin North Am. 2017. [ Journal Article ]
  5. Davis JL, Pandalai P, Ripley RT, Langan RC, Steinberg SM, Walker M, Toomey MA, Levy E, Avital I
    Trials. 12(1): 129, 2011. [ Journal Article ]

Dr. Davis trained in Complex General Surgical Oncology at Memorial Sloan Kettering Cancer Center with an interest in gastric and hepato-pancreato-biliary tumors. He is board certified in both Complex General Surgical Oncology and General Surgery. Dr. Davis completed his surgical training at Indiana University during which time he dedicated three years as a research fellow in Surgical Oncology and Immunotherapy at NCI. 

Position Keywords Contact Name Contact E-mail Number of Positions
Clinical Fellows - Surgical Oncology

Surgical Oncology, Fellowship, Training, Postdoctoral 

Joanna Lamot

Multiple Positions Available
Name Position
Maureen Connolly R.N. Research Nurse
Cathleen Hannah R.N. Research Nurse (Contr.)
Stacy Joyce PA-C Physician Assistant (Contr.)

NIH Genetic and Rare Diseases Information Center

Patients are encouraged to visit the NIH Genetic and Rare Diseases Information Center (GARD) for more information about organizations supporting stomach cancer patients.


Clinical Trial Conversation: Hereditary Diffuse Gastric Cancer